Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 ActivatorsGlobeNewsWire • 10/10/19
Why I Have 28% Of My Retirement Portfolio Invested In These 3 High-Yield Blue ChipsSeeking Alpha • 10/02/19